New drugs for tuberculosis: current status and future prospects

This article reviews two classes of compounds that have advanced into phase II and III clinical trials, long-acting rifamycins and fluoroquinolones, and a number of other drugs that have entered or may enter clinical development in the near future.

Saved in:

Bibliographic Details
Published in:	Clinics in chest medicine Vol. 26; no. 2; p. 327
Main Authors:	O'Brien, Richard J, Spigelman, Mel
Format:	Journal Article
Language:	English
Published:	United States 01-06-2005
Subjects:	Antitubercular Agents - therapeutic use Humans Tuberculosis - drug therapy
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	This article reviews two classes of compounds that have advanced into phase II and III clinical trials, long-acting rifamycins and fluoroquinolones, and a number of other drugs that have entered or may enter clinical development in the near future.
ISSN:	0272-5231
DOI:	10.1016/j.ccm.2005.02.013